Waters (WAT) Down 8.4% Since Last Earnings Report: Can It Rebound?

Core Viewpoint - Waters Corporation has reported strong fourth-quarter earnings, surpassing estimates, but the stock has seen a decline of approximately 8.4% since the last earnings report, underperforming the S&P 500 [1] Financial Performance - Waters reported Q4 2025 non-GAAP earnings of $4.53 per share, exceeding the Zacks Consensus Estimate by 0.67% and reflecting a year-over-year increase of 10.5% [2] - Net sales reached $932.4 million, surpassing the Zacks Consensus Estimate by 0.55%, with a reported increase of 7% year-over-year and 6% on a constant currency basis [2] Segment Performance - The Waters segment generated sales of $823.9 million, up 8% on a reported basis and 7% on a constant currency basis year-over-year, while the TA segment reported flat sales of $108.4 million [3] - Instrument sales were $432.9 million, up 3% year-over-year, Services sales were $329.1 million, increasing 9%, and Chemistry sales were $170.3 million, growing 13% [4] Market Performance - The Pharmaceutical market generated sales of $540.6 million, an 8% increase year-over-year, while Industrial sales were $284.5 million, also up 8%. Government & Academic sales decreased by 2% to $107.3 million [5] - Sales by region included $283.9 million from Asia (up 4%), $332.4 million from the Americas (up 4%), and $315.9 million from Europe (up 13% reported) [6] Operating Expenses - Non-GAAP selling and administrative expenses were $191 million, up 13.3% year-over-year, with an adjusted operating margin of 35.2%, contracting 20 basis points [7] Balance Sheet and Cash Flow - As of December 31, 2025, cash and cash equivalents were $587.8 million, up from $459.1 million in September. The company generated cash from operations of $164.5 million and reported free cash flow of $125.2 million [8] Guidance - For Q1 2026, Waters expects sales growth between 7% and 9% on a constant currency basis, with projected sales of $718-$731 million on an organic reported basis [10] - For FY 2026, the company anticipates constant currency sales growth of 5.5% to 7%, with expected non-GAAP earnings in the range of $14.30 to $14.50 per share, reflecting year-over-year growth of approximately 8.9% to 10.4% [11] Estimate Revisions - Since the earnings release, there has been a downward trend in estimates, with the consensus estimate shifting down by 9.42% [12] VGM Scores - Waters has a subpar Growth Score of D and a Momentum Score of C, with an overall aggregate VGM Score of D, indicating it is in the bottom 40% for value investors [13] Industry Comparison - Waters is part of the Zacks Medical - Instruments industry, where competitor Hologic reported revenues of $1.05 billion, reflecting a year-over-year change of +2.5% [15]